HO
Press Releases
December 9, 2024
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH)


